Eric P. Lefkofsky Sells 84,640 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 84,640 shares of the company’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $80.87, for a total transaction of $6,844,836.80. Following the sale, the chief executive officer now owns 4,964,820 shares of the company’s stock, valued at $401,504,993.40. The trade was a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tempus AI Stock Down 11.2 %

Shares of NASDAQ:TEM opened at $68.09 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The company’s fifty day simple moving average is $50.29 and its 200 day simple moving average is $51.65.

Institutional Trading of Tempus AI

Institutional investors have recently modified their holdings of the company. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the third quarter worth about $30,000. Operose Advisors LLC acquired a new position in Tempus AI during the 4th quarter worth approximately $25,000. Farther Finance Advisors LLC bought a new position in shares of Tempus AI during the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC raised its holdings in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new stake in shares of Tempus AI in the fourth quarter worth $49,000. 24.22% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TEM has been the subject of a number of recent analyst reports. TD Cowen reiterated a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. William Blair lowered shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.